Weekly Digest – March 2026 Weekly Digest – March 2026 9 March 2026: Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer AstraZeneca and Daiichi Sankyo announced that the U.S. FDA has […]
Weekly Digest – March 2026 Weekly Digest – March 2026 09 March 2026: Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma Oncopeptides announced that it has secured fast-track designation in Norway for a planned Window-of-Opportunity clinical study evaluating a […]
Weekly Digest – March 2026 Weekly Digest – March 2026 10 March 2026: ProstACT Global Phase 3 study (part 1) achieves primary objectives Telix Pharmaceuticals announced that Part 1 of the global Phase 3 ProstACT Global trial evaluating its investigational […]
Weekly Digest – March 2026 Weekly Digest – March 2026 10 March 2026: AstraZeneca initiates Phase 3 CLARITY-Gastric 02 trial of AZD0901 combo in CLDN18.2+ gastric cancer AstraZeneca has initiated the Phase 3 CLARITY-Gastric 02 trial evaluating Sonesitatug vedotin (AZD0901) […]
Weekly Digest – March 2026 Weekly Digest – March 2026 6 March 2026: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio Servier and Day One Biopharmaceuticals announced a definitive agreement under which Servier will acquire […]
Weekly Digest – March 2026 Weekly Digest – March 2026 12 March 2026: Fujifilm invests in VALANX Biotech to strengthen ADC CDMO capabilities Fujifilm announced an investment in Austrian biotechnology company VALANX Biotech to strengthen its contract development and manufacturing organization […]
